Foot-and-mouth disease virus

Study on Foot-and-Mouth Disease Virus Results in Submission for Additional EPA Label

Retrieved on: 
Monday, March 11, 2024
Hydrogen, DARPA, Hospital, Restaurant, Hydrogen peroxide, Livestock, Disinfectant, Food safety, Research, Deer, Annual report, Stainless steel, DHS, Animal, Sheep, Goat, Global health, FMD, Meat, Contagious disease, Foot-and-mouth disease virus, COVID-19, School, Virus, FMDV, TAD, EPA, Decontamination, Infection, Police, Science, PIADC, Foot-and-mouth disease, Pharmaceutical industry

This significant advancement supports the Company’s submission for an additional EPA label.

Key Points: 
  • This significant advancement supports the Company’s submission for an additional EPA label.
  • Foot-and-mouth disease (FMD) represents a critical global threat, being an extremely contagious disease affecting a wide range of cloven-hoofed animals including cows, pigs, sheep, goats, and deer.
  • TOMI’s recent study has proven SteraMist iHP technology to eliminate infectious FMDV from both porous (concrete) and non-porous (stainless steel) surfaces in the presence of organic soil load.
  • Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.

SINOVAC Varicella Vaccine Prequalified by WHO

Retrieved on: 
Friday, November 4, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Company, Mumps, Polio, III, World, Influenza A virus subtype H1N1, World Health Organization, WHO, Foot-and-mouth disease virus, Hepatitis A, Vaccine, COVID-19, H5N1, CEO, National TB Elimination Program (India), Chickenpox, Seroconversion, HFMD, Oka, NASDAQ, Infection, R, Streptococcus, EV71, Program, Sinovac Biotech

This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.

Key Points: 
  • This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.
  • Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, Now that SINOVAC has received WHO prequalification for our varicella vaccine, we can provide a new weapon for prevention and control of infectious diseases globally.
  • Previously, three other vaccines by SINOVAC were also approved by WHO in various uses and conditions, including Healive (the hepatitis A vaccine), CoronaVac (the COVID-19 vaccine) and the Sabin-strain inactivated polio vaccine.
  • In 2022, SINOVACs Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC to Showcase Products at CPHI Frankfurt

Retrieved on: 
Friday, October 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, R, Chickenpox, Company, Influenza A virus subtype H1N1, Mumps, NASDAQ, Polio, H5N1, Vaccine, Pyaar Tune Kya Kiya (TV series), Foot-and-mouth disease virus, Booth, EV71, Streptococcus, Program, COVID-19, Infection, HFMD, Hepatitis A, WHO, Sinovac Biotech, Fine chemical

Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the worlds largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.

Key Points: 
  • Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the worlds largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.
  • At Booth#41G20, the first floor of Hall 4, Messe Frankfurt, SINOVAC will greet all visitors of CPHI and present its comprehensive portfolio.
  • Helen Yang, Chief Business Officer of SINOVAC said, SINOVAC is an old friend of CPHI, and we are happy to finally return to CPHIs in-person event for the first time since the outbreak of the COVID-19 pandemic globally.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile

Retrieved on: 
Tuesday, September 6, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Valence (chemistry), COVID-19, CEO, Safety, Program, Influenza A virus subtype H1N1, WHO, NASDAQ, Vaccine, Streptococcus, R, Infection, H5N1, Instituto Butantan, HFMD, Polio, Chickenpox, Hepatitis A, Mumps, ISP, Company, Foot-and-mouth disease virus, RNA transfection, Clinical trial, Delta, EV71, Sinovac Biotech, Omicron

In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.

Key Points: 
  • In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.
  • Mr. Weidong Yin, the Chairman, President, and CEO of SINOVAC said, SINOVAC has made great progress collaborating with global partners in the development and manufacturing of the COVID-19 vaccine.
  • Its COVID-19 vaccine, CoronaVac, has been approved for use in more than 60 countries and regions worldwide.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

Retrieved on: 
Wednesday, August 3, 2022
Biotechnology, Pharmaceutical, General Health, Health, COVID-19, Children, Infectious Diseases, Consumer, NASDAQ, Vaccine, Safety, Foot-and-mouth disease virus, Minor, Department, R, Program, Center, Health Bureau, H5N1, WHO, Scientific Committee on Antarctic Research, Infection, HFMD, Sinovac Biotech, Mumps, III, Scientific Committee on Emerging and Newly Identified Health Risks, Polio, Chickenpox, Hepatitis A, COVID-19, CoronaVac, Company, EV71, Carrie Lam as Chief Executive of Hong Kong, Vaccination, Streptococcus, COVID-19 vaccine, Ageing, Zoonosis, Influenza A virus subtype H1N1, Government

The vaccination schedule for this age group follows the same vaccination schedule of older children.

Key Points: 
  • The vaccination schedule for this age group follows the same vaccination schedule of older children.
  • SINOVAC initiated its COVID-19 vaccine (CoronaVac) phase III clinical studies among children aged 6 months to 17 years since 2021.
  • Preliminary results show the vaccine has a good safety and immunogenicity profile, with no severe adverse reaction reported 6 months after two doses of vaccination among children aged 6 months to 35 months.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile

Retrieved on: 
Tuesday, July 19, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Influenza A virus subtype H1N1, III, Chickenpox, Volunteering, Infection, WHO, Safety, Republic, Polio, Foot-and-mouth disease virus, Program, EV71, PI, NASDAQ, Sinovac Biotech, COVID-19, Company, Hepatitis A, Ageing, Mumps, Streptococcus, H5N1, Vaccine, Clinical trial, HFMD, R, Coro de la Pontificia Universidad Católica de Puerto Rico

This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.

Key Points: 
  • This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.
  • In total, there will be 1,600 volunteers recruited, half of whom will receive 1 dose of SINOVACs inactivated quadrivalent influenza vaccine, and the other half will receive a different quadrivalent influenza vaccine commercially available in Chile.
  • Children aged between 3 and 8 of both groups who havent received any influenza vaccine will receive 2 doses of influenza vaccine.
  • The upcoming clinical trial in Chile will provide further evidence on the efficacy and safety of SINOVACs quadrivalent influenza vaccine.

SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil

Retrieved on: 
Thursday, July 14, 2022
COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, COVID-19, Influenza A virus subtype H1N1, Program, Pulmonology, Vaccine, H5N1, Infection, HFMD, SBP, WHO, Vaccination, Company, Hepatitis A, R, Mumps, Foot-and-mouth disease virus, Ageing, Brazilian Association of Investigative Journalism, Minor, SBI, Chickenpox, Instituto Butantan, Sinovac Biotech, Research, Association, CoronaVac, EV71, Streptococcus, To Brazil!, NASDAQ, Polio, Pharmaceutical industry, Brazilian Health Regulatory Agency, COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science

This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.

Key Points: 
  • This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.
  • To assist Anvisa in evaluating the vaccine, the experts from the above institutions had access to technical materials and research data on the vaccine.
  • CoronaVac has been authorized for emergency use for adults in Brazil since January 17, 2021.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

Retrieved on: 
Saturday, June 25, 2022
Biotechnology, Pharmaceutical, Health, COVID-19, Influenza A virus subtype H1N1, Research, SAHPRA, Chinese government award for outstanding self finance students abroad, Polio, COVID-19, South African Health Products Regulatory Authority, Company, Hepatitis A, Hepatitis, Ageing, Infection, H5N1, Streptococcus, Sinovac Biotech, Risk management, Foot-and-mouth disease virus, NASDAQ, Vaccine, HFMD, Chickenpox, Safety, Mumps, EV71, WHO, Pharmaceutical industry

All the evidence suggested that the SINOVAC COVID-19 vaccine was safe and effective.

Key Points: 
  • All the evidence suggested that the SINOVAC COVID-19 vaccine was safe and effective.
  • SINOVAC COVID-19 vaccine has been available in more than 60 countries, with a total supply of almost 2.9 billion doses.
  • Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
  • SINOVAC has been continually dedicating itself to new vaccine research and development, with more combination vaccine products in the pipeline, and constantly exploring opportunities in the international market.

Codagenix Welcomes Bruce Taillon as Executive Vice President of Animal Health

Retrieved on: 
Wednesday, January 12, 2022
Business development, Foot-and-mouth disease virus, Research, Technology, Degenerative disease, University, Vaccine, Roche Diagnostics, Dog, United States Department of Agriculture, Solution, Farmer, Animal Health, Leadership, National Institute, Health, Disease management, Animal, View, National Academy of Sciences, Miniature pig, Multimedia, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Carnegie Mellon University, Washington University in St. Louis, Livestock, Horse, Business, National academy, Drug discovery, National Society of Certified Healthcare Business Consultants, List of life sciences, Management, Biology, Taillon

FARMINGDALE, N.Y., Jan. 12, 2022 /PRNewswire/ -- Codagenix, Inc., a clinical-stage synthetic biology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced the appointment of Bruce E. Taillon, Ph.D., as Executive Vice President of Animal Health.

Key Points: 
  • FARMINGDALE, N.Y., Jan. 12, 2022 /PRNewswire/ -- Codagenix, Inc., a clinical-stage synthetic biology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced the appointment of Bruce E. Taillon, Ph.D., as Executive Vice President of Animal Health.
  • "His vast knowledge and passion for animal health is evident in his diverse track recordfrom technical operations to vaccine development and pharmaceutical innovation."
  • Prior to joining Codagenix, Taillon served as Senior Director of External Innovation & Business Development of Elanco Animal Health, where he led a global team in the identification and evaluation of new and innovative animal health solutions.
  • "I'm thrilled to join the progressive team at Codagenix as they pioneer new frontiers in vaccine development for animals," said Taillon, Executive Vice President of Animal Health at Codagenix.

Tetracore, Inc. Introduces First USDA-Licensed Real-Time PCR Test for the Detection of Foot and Mouth Disease Virus in Bovine, Swine and Ovine

Retrieved on: 
Friday, June 11, 2021
Natural sciences, Laboratory techniques, Chemistry, Physical sciences, Molecular biology, Biotechnology, Polymerase chain reaction, Reverse transcription polymerase chain reaction, Real-time polymerase chain reaction, Assay, Foot-and-mouth disease virus

The VetAlert FMDV RNAhigh-performance test kit was developed by Tetracore scientists and will be commercialized and sold by Tetracore.

Key Points: 
  • The VetAlert FMDV RNAhigh-performance test kit was developed by Tetracore scientists and will be commercialized and sold by Tetracore.
  • Nearly two decades ago, Tetracore validated and published a real-time RT-PCR assay for FMDV, as described by Callahan et al.
  • The primer and probe set from the publication became part of the OIE and USDA reference test methods.
  • Tetracore is a biotechnology company specializing in the development and manufacture of diagnostic devices and assays for the detection of infectious diseases.